

## Index

- ACE inhibitors, 16, 97, 334, 351, 390; in Australia, 136, 139, 149; in Denmark, 263; in Israel, 370–71; in Japan, 169–70; in the U.S., 38, 49
- ÅDEL-reform* (Sweden), 208, 225
- Advanced cardiac life support, 38, 98
- Adverse selection problems, 346, 347
- Age difference, 3, 21, 385, 394 (*see also* Elderly patients); in Israel, 382; in Italy, 332, 343; in Korea, 191; in the U.S., 31, 35
- Alberta, AMI care in, 88–103; consequences of changes in, 99–102; expertise in, 98–99; financing of, 89–92, 100–102; health outcomes, 99–100; low-tech, 97–98; mortality and, 88, 99–100, 102–3; regulation and, 92–93; technological change in, 94–98
- Alberta Acute Care Funding System, 91
- Alberta Health Insurance System, 89
- Alteplase. *See* Tissue plasminogen activator (tPA)
- AMI (acute myocardial infarction), 16–17 (*see also* AMI care in *specific country, Canadian province*); recurrent, 42–45, 127, 136, 139, 145–46, 151, 222
- Angina, 113, 130–32, 151, 220, 254, 261, 263; in Israel, 374, 381
- Angiography, 48, 80, 98 (*see also* Cardiac catheterization); in Australia, 127–28, 130–32, 136, 146, 151; in England, 273, 277–79; in Finland, 238, 241; in Japan, 175; in Quebec, 76, 78; in Sweden, 210, 217
- Angioplasty, 389, 390, 391–92 (*see also* PTCA); balloon, 293, 369, 381; in Canada, 76, 84–86, 102; in Finland, 238, 241–43; in France, 297; in the U.S., 14–15, 24, 38, 41, 48, 49, 50
- Anticoagulants, 263, 281, 351. *See also* Streptokinase
- Antiplatelet agents, 284, 302, 334, 351, 353; in Australia, 128, 136–39, 149, 151
- Arrhythmias, 216, 374
- Aspirin, 15, 16, 151, 170, 392; in Canada, 97–98, 113; in Europe, 220, 245, 281, 354; in Israel, 370; in Taiwan, 200; in the U.S., 36–38, 41, 48, 50
- Australia, AMI care in, 11, 12, 121–53, 389; cardiac complications and, 139–43; consequences of changes in, 139–42; effects of incentives on, 146–52; high-tech, 126–36; hospitals in, 13, 121, 122–23; incentives for technological change in, 122–25; insurance in, 123; low-tech, 136–39; medical expenditures and, 142–46; MONICA Project in, 122–25, 139; mortality and, 127, 136, 139–42, 393; payment in, 18, 124; in Perth,

- Australia (*continued*)  
 125–32; specialists in, 122, 123, 150; technological change in, 125–39; treatment rates in, 150; in Victoria, 132–36
- Balloon angioplasty, 293, 369, 381
- Belgium, AMI care in, 306–21; consequences of changes in, 314–18; effects of incentives on, 319–21; financing of, 307–8; high-tech, 310–13; incentives for technological change in, 307–9; low-tech, 313–14; medical expenditures and, 318, 321; mortality and, 316–17, 321; payment system for, 18; physician supply in, 13; technological change in, 309–14; technology regulation and, 308–9
- Beta-blockers, 15, 392; in Alberta, 97–98; in Australia, 136–39, 149; in Belgium, 313; in England, 281; in Finland, 245; in France, 302; in Israel, 370, 371; in Italy, 334; in Japan, 170; in Ontario, 70; in Sweden, 220; in Switzerland, 351, 353; in the U.S., 26, 36–37, 38, 48
- Blue Cross, 90, 97
- Brianza, Italy, 334, 337
- British Cardiac Intervention Society, 279
- Budget caps, 121
- Budget systems, global, 18 (*see also* Financing of care); in Belgium, 108, 307; in Denmark, 253–54, 265–66; in England, 271, 284; in France, 289–90, 291, 293, 299; in Italy, 347; in Sweden, 211, 213, 223, 225; in Switzerland, 354
- Bureau of National Health Insurance (Taiwan), 196, 205
- Bypass surgery (CABG), 15, 24, 385, 389, 391–92 (*see also* CABG); in Australia, 133; in England, 284; in Finland, 238; in Japan, 175; in Quebec, 76–77, 78; in the U.S., 24, 29, 31, 48, 49
- CABG (coronary artery bypass graft), 29, 133, 241, 253, 297–98 (*see also* Bypass surgery); in Australia, 127–28, 130, 151; in Belgium, 310–14, 318, 319, 321; in Canada, 55, 61, 63, 65–66, 68, 93, 95–97, 102, 109–11; in Denmark, 254, 255, 257–58, 259–60, 264, 265; in England, 271, 273, 277–79, 281; in Finland, 248; in France, 292, 295, 300, 302; in Israel, 358–59, 364–65, 366–67; in Italy, 331–32, 336; in Japan, 160, 164–65, 167, 171, 173; in Korea, 185, 186, 188–91; in Sweden, 210, 215, 217, 227; in Switzerland, 349; in Taiwan, 196–97, 198, 199–200, 204–5, 206
- Calcium antagonists, 263, 351, 353
- Calcium channel blockers, 392; in Alberta (Can.), 97, 98; in Belgium, 313; in Finland, 245; in France, 302; in Israel, 370, 371; in Japan, 169; in the U.S., 37, 38, 48
- California, 28, 29, 42, 49
- Canada, 12, 14, 18, 115–16 (*see also* Alberta; Manitoba; Ontario; Quebec); fee-for-service in, 55, 60, 75, 90; IHD in, 156; insurance in, 13, 116; medical expenditures in, 58, 100–102, 106
- Canadian Health Act, 55, 73
- Canadian Institute for Health Information (CIHI), 59, 63
- Cancer, 4, 6, 7, 41, 116, 396–97
- Cardiac catheterization (angiography), 14–15, 16, 338, 385, 389; in Belgium, 310–13; in Canada, 60, 65–66, 93, 95–97, 102; in Denmark, 254, 255, 257–58, 259–60, 265; in France, 295, 297, 298, 299,

- 300, 301; in Israel, 358–59, 365–66, 377; in Italy, 331–32; in Japan, 171, 175; laboratories for, 6, 12, 55, 309; in Sweden, 217; in Taiwan, 198, 199, 206; in the U.S., 29, 34, 48, 49, 50
- Cardiac complications, 139–42
- Cardiac surgery centers: in Belgium, 308, 309, 314, 318, 321; in Finland, 250
- Cardiologists, 50, 176, 214, 258, 279, 367; in Belgium, 308; in England, 284; in Japan, 171; in Korea, 190
- Cardiology, 283, 285, 309
- Cardiothoracic surgery, 275, 283, 285
- Cardiovascular disease, 184, 252, 330
- CATH. *See* Angiography; Cardiac catheterization
- Catheters, 293, 354
- Cause of Death Data File (Taiwan), 194
- Center for Interdisciplinary Study in Health Economics (CIES), 306–7, 309
- Central Bureau of Statistics (Israel), 364
- Charlson comorbidity index, 63, 65
- Clinical Quality Improvement Network, 99
- Clinical Standards Advisory Group (England), 270, 275–77, 278, 281, 283
- Commissione Unica del Farmaco (Italy), 328
- Commonwealth Department of Health (Australia), 123
- Comorbidity, 63, 65, 94, 111, 143, 146, 364
- Competition, 3, 13, 358; among managed-care plans, 27; in Belgium, 307; in Denmark, 256; in Finland, 238–39; in France, 294; in Italy, 328–29; in Korea, 187, 191; in Sweden, 225; in Switzerland, 348; in Taiwan, 197; in the U.S., 26–27
- Congestive heart failure, 43–45, 373
- Consumer information, 187, 191
- Copayments, 11; in Australia, 133; in Belgium, 308; in England, 272; in France, 290, 291; in Italy, 325, 326; in Japan, 159; in Korea, 186; in Manitoba, 116; in Sweden, 211; in Switzerland, 346–47; in the U.S., 24
- Coronary angiography. *See* Cardiac catheterization
- Coronary arteriography, 353
- Coronary artery procedures (CARPs), 113, 127, 130–32, 143, 151. *See also* Stenting
- Costs (*see also* Financing of care; Medical expenditures): in Australia, 124; containment of, 102, 174, 308, 348, 359, 392; resource, 1
- Danish Medical Association, 254, 257
- Data limitations, 2, 177, 336
- Death registry, 330. *See also* Mortality
- Defibrillators, 36, 216, 259
- Demographic data, 63–65
- Denmark, AMI care in, 252–66; appropriateness of, 263–64; competition and, 13, 256; consequences of changes in, 264–65; financing of, 253–55, 265; high-tech, 259–61; incentives for technological change in, 253–58; low-tech, 263; medical expenditures and, 265; mortality and, 252, 264; physician supply in, 13, 258; regulation in, 12, 255–56; special interest groups in, 257; technological change in, 258–64; waiting lists and, 252, 256, 257, 259

- Diabetes, 4, 6
- Diagnosis-related group (DRG) systems, 211, 225, 237, 308, 338; of Australia and Taiwan, 11; in Canada, 91; codes, 143–46, 286, 330; data, 295; in France, 302–3; in Italy, 326–27, 330, 337, 347; payments for, 49; in the U.S., 24, 36, 47
- Diagnostic catheterization. *See* Cardiac catheterization
- Diagnostic testing, 113
- Diuretics, 263, 334, 351
- Drugs, 151, 159 (*see also* Low-tech treatments; Thrombolytic drugs; *and specific drugs*); antiarrhythmics, 281, 351; in Australia, 124; in Belgium, 308, 318, 321; cardiac, 36, 70, 75, 79, 80, 83, 139; cholesterol-lowering, 7, 38, 49, 97, 136; costs in Taiwan, 201; in Denmark, 255, 263; and device regulation, 3–4, 293–94; expenditures, 92; in Finland, 245; in Italy, 327, 334; in Japan, 116, 159, 176; pharmaceuticals, 116, 214, 243; prescription, 24, 26, 272, 292; in Sweden, 211, 214
- Drug therapies, 16, 28, 59–60, 75, 92–93, 97
- Elderly patients, 34–36, 65–69, 375 (*see also* Age difference); in the U.S., 21, 29–30, 42, 47, 49
- Electrocardiogram (ECG), 137, 259
- England, AMI care in, 4, 6, 11, 16, 268–87, 393; appropriateness of, 281; consequences of changes in, 281; economy and, 272; expenditures for, 283–84; financing of, 18, 271–72; gatekeeper requirements in, 308; health outcomes in, 282–83; high-tech, 277–79; hospitals and, 13, 273–74; incentives for technological change in, 271–75; low-tech, 279–81; medical expenditures and, 283–84; mortality in, 270, 283, 284, 286; national expectations for, 274–75; reimbursements in, 391; technology regulation and, 12, 272–73
- Equity, 380; of Canadian health care system, 106; in Finland, 239
- European Commission, 256, 327
- European Medical Agency (EMEA), 327
- European Union, 325, 327
- Expenditures. *See* Medical expenditures
- Federal Law on Sickness and Accident Insurance (Switzerland), 345–46, 348
- Federal Law on Sickness Insurance (Switzerland), 345, 347–48, 354
- Fee-for-service system, 12, 390–91; in Belgium, 319; in Canada, 55, 60, 75, 90; in Denmark, 254; in France, 292; in Israel, 358; in Japan, 159; in Korea, 186; in Taiwan, 193, 196
- Financing of care (*see also* Costs; Insurance; Medical expenditures; Reimbursement): in Canada, 59–60, 73, 75, 76, 89–92, 100–102; in Israel, 357–58; in the U.S., 22–25
- Finland, AMI care in, 233–50, 252, 389; competition and, 238–39; consequences of changes in, 246–48; economy of, 237, 248; financing of, 18, 235–38; high-tech, 241–43; incentives for technological change in, 235–40; low-tech, 243–45; malpractice liability and, 239; MONICA study in, 240, 241, 245; mortality and, 133, 234, 246; municipalities of,

- 235–37; regulation and, 12, 238; regulation of physician supply and, 239–40; technological change in, 240–45
- Food and Drug Administration (FDA), (U.S.), 25–26, 49, 256
- France, AMI care in, 13, 289–303, 389; competition and, 294; drug and device regulation and, 293–94; financing of, 290–92; incentives for technological change in, 290–95; medical expenditures and, 289; MONICA Project in, 301; regional inequalities in, 293; regulation and, 12, 292–94; technological change and, 295–302
- Fribourg, Switzerland, 344, 349, 352
- Friuli region (Italy), 323, 330, 334, 337
- Fukuoka Prefecture (Japan), 158, 164
- Gallbladder disease, 4, 6
- General practitioners, 253, 254, 268, 272, 292, 350
- Geriatric medicine, 274. *See also* Elderly patients
- Germany, 4, 156
- Gruppo Italiano di Studi Emodinamici, 334
- Health Care Insurance Plan, 89–92
- Health Departments: England, 270; France, 292; Taiwan, 194; Western Australia, 126, 143
- Health Insurance database (Belgium), 309
- Health maintenance organizations (HMOs), 212
- Health Ministry (Canada), 92
- Health outcomes, 1, 5–8, 17, 72, 393 (*see also* Mortality); in Belgium, 306, 314–18; in England, 282–83; in Finland, 246–48; in Israel, 372–76, 380–82; in Italy, 336–37; in Japan, 171–74; in Manitoba, 113; regional differences in, 102, 336, 338; in Sweden, 220–22; in Taiwan, 200; in the U.S., 40–47
- Heart disease, ischemic. *See* Ischemic heart disease
- Heart failure, 16, 50, 145–46, 151, 220–22, 254; chronic, 163
- Heart Plan 1993 (Denmark), 257–58
- Heparin, 36–37, 170
- High-tech treatments, 12, 14–15, 385, 389, 393 (*see also* Angioplasty; Bypass surgery; Cardiac catheterization); in Australia, 126–36; in Belgium, 310–13, 319; in Canada, 95–97, 108, 109–12; in Denmark, 259–61; in Finland, 241–43; in Israel, 364–69; in Italy, 330, 331–34, 337; in Japan, 166–69, 173; in Manitoba, 109–12; in Sweden, 216–20; in Switzerland, 349; in Taiwan, 199–200; in the U.S., 24, 29–36, 48, 49, 50
- Hospital Claim File (Taiwan), 194–95, 198
- Hospital Discharge Register (Finland), 234, 240–41, 243, 246
- Hospital Episode Statistics (England), 270, 275–77, 281–82
- Hospitalization Benefits Plan (Canada), 89
- Hospitalization data, 94–95
- Hospitals (*see also* Length of stay): in Belgium, 308; CCUs, 350, 358, 363; corporate, 191; in Denmark, 261–63; in Finland, 248; ownership of, 10, 13, 173, 197; private, 122–23, 173, 191, 229n. 18, 256, 291, 359; public, 121, 122, 256, 291, 293, 296, 347; reimbursement of, 24, 359; in Switzerland, 343–44, 347; teaching, 13, 106, 111; university, 235

- Hypertension, 139, 314
- ICD9 codes, 163, 198, 240, 258; in Belgium, 309; in Canada, 95, 108; in Israel, 356–57, 369, 381; in Italy, 330, 337
- IHD. *See* Ischemic heart disease
- Income, 3, 115, 116
- Inpatient care, 2, 45–47, 211, 235, 259
- Institute for Clinical Evaluative Sciences, 61
- Institute for Pharmaco-Economics, 93
- Insurance, 3, 13, 116, 291 (*see also* Financing of care; Payment systems; Reimbursement); in Australia, 123; in Belgium, 307–8; employer-provided, 24, 239; in England, 272; in Israel, 358; in Italy, 325, 347; in Japan, 158, 159; in Korea, 184; private, 11, 24, 75, 97, 150, 290; in Switzerland, 345–48, 353
- Ischemic heart disease (IHD), 6–7, 84, 85, 163, 381; in Australia, 125, 131, 136, 139, 145–46, 150, 152; in Japan, 156; in Korea, 184; in Taiwan, 193, 205; in the U.S., 21, 25, 29, 42–45
- Israel, AMI care in, 356–82, 389; data sources for, 357, 362–63; effects of technological change in, 377–80; health outcomes, 372–76, 380–82; high-tech, 364–69; incentives for technological change and, 357–62; low-tech, 370–71; medical expenditures and resources, 356, 376–77; mortality, 356–57, 364, 372–74, 375, 381; regional differences in, 371–72
- Israel Central Bureau of Statistics, 356
- Israel Medical Association, 362
- Israel Society for the Prevention of Heart Attacks, 363
- Italian Association of Hospital Cardiologists, 336
- Italy, AMI care in, 323–39; appropriateness of, 334–36; competition and, 328–29; financing of, 324–25; health outcomes and, 336–37; high-tech, 331–34; incentives for technological change in, 324–30; low-tech, 334; medical expenditures and, 337; MONICA Project and, 339; mortality and, 330, 339; payment system and, 326–28, 336, 338; physician recruitment and, 329; regional differences in, 326, 336, 338; regulation and, 327–28; technological change in, 330–36
- Japan, AMI care in, 12, 18, 156–80, 390; appropriateness of, 171; fee-for-service in, 173–74; health outcomes and, 171–74; high-tech, 166–69, 173; hospital ownership and, 13, 173; IHD in, 156; incentives for technological change in, 159–63; insurance for, 13, 158, 159; length of stay and, 173–74; low-tech, 169–71; medical expenditures and, 2, 173; mortality and, 163, 171–73, 176, 177; physician supply in, 13; reimbursement in, 159–60; technological change in, 163–71; thrombolytic drugs for, 164–65, 169–71
- Korea, AMI care in, 12, 13, 184–91; financing of, 186–87; high-tech, 185, 188–91; hospitals in, 188, 191; incentives for technological change in, 186–88; incentives for technology use, 187–88; patient payments in, 11

- Koseisho (Japanese Ministry of Health and Welfare), 159, 163
- Length of stay (LOS), 376; in  
Canada, 99–100, 113; in European  
countries, 225, 248, 300, 318; in  
Japan, 173–74; in Taiwan, 203,  
204–5; in the U.S., 34–36
- Lidocaine, 37–38, 48, 97, 392
- Life expectancy, 5, 115, 116, 252, 264
- Lipid-lowering agents, 136, 149, 255,  
256
- Local Health Units (Italy), 325–26,  
328
- Lombardy, Italy, 334–36
- Long-term care, 24, 208
- Low-tech treatments (*see also* ACE  
inhibitors; Aspirin; Beta-blockers;  
Drugs; Thrombolytic drugs): in  
Australia, 136–39; in Belgium,  
313–14; in Canada, 97–98, 112–13;  
changes in, 15–16, 390; in Den-  
mark, 263; in England, 277–81,  
286; in Finland, 243–45; in Israel,  
370–71; in Italy, 330, 334, 338; in  
Japan, 169–71; in Sweden, 220; in  
Switzerland, 350–53; in Taiwan,  
200; in the U.S., 49
- Macroregulation, 12, 26, 384
- Malpractice, 14, 27, 62, 214, 239,  
329
- Managed-care plans, 25, 26, 49, 50
- Manitoba, AMI care in, 106–7,  
112–13, 394; changes in resource  
use, 113–15; consequences of  
changes in, 113–15; high-tech,  
109–12; low-tech, 108, 112–13;  
patient demographics, 109–10;  
queue management and, 109; tech-  
nological change in, 108–13
- McKinsey Global Research Insti-  
tute, 4, 5–6
- Med-Echo, 79, 80
- Medicaid (Korea), 186
- Medicaid (U.S.), 24, 26
- Medical Benefits Regulations  
(Canada), 90
- Medical expenditures, 2–5, 8, 18–19  
(*see also* Costs; Financing of care;  
Insurance; Reimbursement); in  
Australia, 142–46; in Belgium,  
318, 321; in Canada, 58, 100–102,  
106; in Denmark, 265; in England,  
283–84; in France, 289; in Israel,  
356, 376–77; in Italy, 325, 337; in  
Japan, 2, 173; in Sweden, 223–25;  
in Switzerland, 343; in the U.S., 2,  
22, 45–47, 124, 174
- Medical Products Agency (Sweden),  
212, 220
- Medicare (Australia), 123
- Medicare (U.S.), 12, 22–25, 26, 28,  
47–48, 49, 116; reimbursement of,  
50, 391
- Medications. *See* Drugs; *and specific  
medications*
- Medisave (Singapore), 11
- Microregulation, 12–13, 348, 360,  
384
- Ministry of Budget (Italy), 326
- Ministry of Education and Universi-  
ties (Italy), 329–30
- Ministry of Health (MOH): Den-  
mark, 255; Israel, 357, 358–59,  
362, 363, 364, 369, 372, 374, 380;  
Italy, 327, 328, 330, 338; Ontario  
(Can.), 60, 61
- Ministry of Health and Welfare  
(Japan), 159, 163
- Ministry of Health and Welfare  
(Korea), 185
- MONICA Project, 6–8, 17, 136,  
264–65, 385; in Australia, 122–25,  
139; in Finland, 240, 241, 245; in  
France, 301; in Israel, 363, 373; in  
Italy, 330, 334; in Sweden, 216; in  
Switzerland, 344–45, 349

- Mortality, 7, 17, 21, 393–94; in Alberta (Can.), 88, 99–100, 102–3; in Australia, 127, 136, 139; in Belgium, 316–17, 321; in Denmark, 252, 264; in England, 270, 283, 284, 286; in Finland, 133, 234, 246; in France, 289; in Israel, 356–57, 364, 372–74, 375, 381; in Italy, 336–37; in Japan, 163, 171–73, 176, 177; in Manitoba (Can.), 113; in Ontario (Can.), 55, 59, 66, 68–69; in Quebec (Can.), 80, 83–84, 86; in Sweden, 209, 216, 220; in Switzerland, 343; in Taiwan, 198, 200; in the U.S., 40, 41, 42, 49, 115
- Mutuelles* (France), 290–91
- National Base for Public Hospitals (France), 296–99
- National Board of Health (Denmark), 257, 258, 265, 266
- National Board of Health and Welfare (Sweden), 208, 212, 215, 220, 227
- National Corporation of Pharmacies (Sweden), 212, 220, 227
- National Cost Base for Public Hospitals (France), 295–300
- National Facility Survey (Japan), 160
- National Health Care Evaluation Agency (France), 293
- National Health Insurance, 359; Denmark, 253, 254, 256; Finland, 235; Korea, 186, 191; Taiwan, 193, 196–98, 198, 200, 205
- National Health Service (England), 268, 270, 273, 274, 277, 284; data from, 281; hospitals of, 271, 275; incentives in, 284; patients of, 278
- National Health System (Italy), 324–25, 328, 334
- National Insurance Institute (Israel), 359
- National Patient Register (Denmark), 258, 261
- National Population Registry (Israel), 363–64
- National Registry of Myocardial Infarction (U.S.), 28, 37
- Netanyahu Commission of Inquiry (Israel), 359
- Nitrates, 36–37, 97–98, 113, 136, 245, 351
- Nitroglycerin, 170, 220
- Nottingham Heart Attack Register (England), 270, 275–77, 281, 282
- Nurses, 50, 97, 98
- Nursing homes, 116, 208
- Odense University Hospital (Denmark), 263
- Office of Health Economics (England), 283
- Ontario, AMI care in, 12, 55–56, 58–70, 91, 389; financing of, 59–60; mortality and, 55, 59, 66, 68–69; queue management in, 109; technological change and, 59–66; trends in health outcomes, 66–70
- Ontario Drug Benefit (ODB) plan, 58, 61
- Ontario Health Insurance Plan (OHIP), 58, 59
- Open-heart surgery, 217
- Organisation for Economic Cooperation and Development (OECD), 124, 268–69, 345
- Oxford Record Linkage Study, 270, 275, 278, 282, 284, 287
- Payment systems, 10, 18, 307 (*see also* Fee-for-service system; Reimbursement); in Australia, 124; Belgium, 309; capitation payments, 254; in England, 274; in Italy,



- 326–28, 336, 338; in Japan, 159, 173; out-of-pocket, 11, 187, 193, 347, 354
- Perth, Australia, 122, 125–32, 146
- Pharmaceuticals, 116, 214, 243. *See also* Drugs; Thrombolytic drugs
- Physicians (*see also* Cardiologists; Specialists; Surgeons): general practitioners, 253, 254, 268, 272, 292, 350; primary, 25, 212, 328; reimbursement of, 60, 75, 86, 90, 97 (*see also* Fee-for-service system); services of, 4
- Physician supply regulation, 13; in Australia, 121; in Canada, 62; in European countries, 239–40, 258, 274, 294–95; in Israel, 361; in Taiwan, 197
- Poor people, in Canada, 116
- Prevention, 7, 233
- Primary physicians, 25, 212, 328
- Private hospitals, 122–23, 173, 191, 229n. 18, 256, 291, 359
- Provider decisions, 294
- PTCA (Percutaneous transluminal coronary angioplasty), 24, 298; in Australia, 127–31, 151; in Belgium, 310–14, 318, 319; in Canada, 55, 60–61, 63, 65–66, 67, 93, 95–97, 102, 109–11; in Denmark, 254, 255, 257–58, 259–60, 264, 265; in England, 271, 273, 277–79, 281; in Finland, 248; in France, 293, 295, 301; in Israel, 358–59, 366–67, 369, 377, 379; in Italy, 327, 331–32, 336; in Japan, 160, 164–66, 167–69, 171, 173–75, 176, 188–91; in Korea, 185, 186; in Sweden, 210, 214–16, 217–20, 227, 230nn. 28–29; in Switzerland, 349; in Taiwan, 196–97, 198, 199–200, 206; in the U.S., 29, 31
- Public hospitals: in Australia, 121, 122; in Europe, 256, 291, 293, 296, 347
- Quebec, AMI care in, 55–56, 72–86, 393–94; consequences of change in, 80–84; incentives for technological change in, 73–78; mortality and, 80, 83–84, 86
- Queues, 109, 150, 210–11, 256, 257, 358. *See also* Waiting lists
- Q-wave infarctions, 41, 102
- Radiologists, 214, 392
- Readmission, 124, 127, 150, 163, 313; in Australia, 132, 142, 145–46; in the U.S., 42–45, 49, 50
- Recurrent AMI, 42–45, 127, 136, 139, 145–46, 151, 222
- Régie de l'Assurance Maladie du Québec (RAMQ), 75, 79, 80, 83
- Regional health authorities, 93
- Regression models, 395–96
- Regulation, 3, 10, 292–94, 357, 390; in Belgium, 308–9; in Canada, 60–62, 76, 92–93; of drugs and devices, 4, 293–94; in Israel, 360, 379; in Italy, 327–28; macro-, 12, 26, 384; micro-, 12–13, 348, 360, 384; in Taiwan, 197; in the U.S., 25–26
- Regulatory Medical References, 294
- Rehabilitation programs, 10, 371
- Reimbursement, 10, 11, 174, 191 (*see also* Fee-for-service system; Financing of care; Insurance; Medical expenditures; Payment systems); to hospitals, 24, 359; in Israel, 376–77, 379; in Italy, 337, 338, 347; in Japan, 159–60, 176; of physicians, 60, 75, 86, 90, 97
- ReoPro (inhibitor), 360
- Resource use, 8, 380; in Australia, 142–46; in Manitoba, 113–15

- Revascularization, 15, 237, 238, 259, 385, 394 (*see also* Angioplasty; Bypass surgery; CABG; PTCA); in Australia, 127, 131–32, 136, 149, 150, 152; in Canada, 55, 59, 60, 70, 76, 80, 109, 113; in Denmark, 257; in England, 271; in Israel, 360, 367; in Italy, 336; in Japan, 75, 171; in Korea, 188; in the U.S., 34, 41, 50
- Service d'Aide Médicale d'Urgence (SAMU), 291, 293
- Sex differences, 42, 95–97; in Australia, 142, 146; in Belgium, 321; in Finland, 247–48; in Israel, 369, 374, 375–76, 382; in Italy, 332, 343, 347; in Manitoba (Can.), 109, 113
- Sickness funds (*see also* Insurance): in France, 290–91, 292; in Israel, 348, 359–60, 361, 372, 379
- Singapore, 11
- Smoking, 7, 136
- Social Health Insurance system (Sweden), 212
- Social Insurance Institution (Finland), 235
- Social Medical Treatment Survey (Japan), 163
- Socioeconomic status, 397
- Specialists, 25, 27, 62, 253, 361–62, 392 (*see also* Cardiologists; Surgeons); in Australia, 122, 123, 150
- Statins, 97, 263, 381
- Stenting, 34, 128, 133, 220, 284, 360 (*see also* PTCA); in Denmark, 255; in France, 293; in Israel, 367, 369, 381; in Korea, 186; in Switzerland, 349
- Strasbourg, France, 301
- Streptokinase, 37, 60, 98, 263, 294, 309, 390; in Israel, 360, 370; in Switzerland, 352, 354
- Stroke, 7, 139, 396
- Surgeons: cardiac, 190, 197, 258; cardiothoracic, 286; cardiovascular, 171, 176, 392
- Surgery, 4, 217. *See also* Cardiac surgery centers; Cardiothoracic surgery
- Sweden, AMI care in, 11, 13, 208–27, 392; consequences of changes in, 220–22; global budget system of, 18; high-tech, 216–20; incentives for technological change in, 209–15; low-tech, 220; malpractice in, 214; medical expenditures and, 223–25; MONICA Project in, 216; mortality and, 209, 216, 220; regulation in, 12, 212–13; system of, 208–9; technological change in, 215–20
- Swedish National AMI Register, 215–16
- Swedish National Inpatient Register, 215
- Swedish National Registry for Cardiac Intensive Care (RIKS-HIA), 216
- Swedish Register for Coronary Angioplasty, 216
- Swiss Federal Social Insurance Office, 345
- Switzerland, AMI care in, 343–55; change in, 348–53; competition in, 348; financing of, 345–48; high-tech, 349; incentives for technological change in, 345–48; incentives for technology use in, 348; insurance competition in, 13; low-tech, 350–53; medical expenditures and, 343; MONICA Project in, 344–45, 349
- Taiwan, AMI care in, 193–206; consequences of, 200–205; DRG system of, 11; financing of, 196–97;

- high-tech, 199–200; incentives for technological change in, 196–98; low-tech, 200; mortality and, 198, 200; technology regulation in, 197
- Taxation, 235, 236, 253, 307
- Tax revenues, 22, 73
- Teaching hospitals, 13, 106, 111
- Technological Change in Health Care (TECH) Global Research Network, 9, 15, 18, 395
- Thrombolysis, 285, 314, 373
- Thrombolytic drugs, 16, 390 (*see also* Streptokinase; *and specific drugs*); in Australia, 136–39, 149; in Belgium, 309, 312–13, 318, 321; in Canada, 59, 70, 97–98, 113; in Denmark, 261, 263; in England, 279–81; in Finland, 245; in France, 291, 293–94, 302; in Israel, 370, 371, 381–82; in Italy, 334; in Japan, 164–65, 169; in Korea, 175; in Sweden, 216, 220, 227; in Switzerland, 350–53; in Taiwan, 200, 206; in the U.S., 36–37, 38, 48, 49, 50
- Ticino canton, Switzerland, 352–53
- Tissue plasminogen activator (tPA), 37, 60, 263, 294, 309, 318, 390
- Tort Act (Sweden), 214
- United Kingdom, 270, 271, 275, 284. *See also* England
- United States, AMI care in, 4, 6, 21–50, 327, 332, 390; appropriateness of, 38–39; competition in, 13, 26–27, 49; consequences of changes in, 40–47; drug use in, 170; effects of incentives, 47–51; expertise in, 38–40; financing of, 22–25; high-tech, 29–36, 389; IHD in, 156; incentives for technological change, 22–27; life expectancy in, 115; low-tech, 36–38; malpractice and, 14, 329; medical expenditures in, 2, 22, 45–47, 124, 174; mortality and, 40, 41, 42, 109, 115; ownership of hospitals in, 13; payment system of, 18; physician supply in, 13; price levels of, 393; regulation and, 12, 25–26, 212; specialization in, 27; technological change and, 28–40; uninsured in, 24; utilization review in, 308
- Urokinase, 390
- Utilization review, 308, 348
- Varsinai-Suomi, Finland, 241–43
- Vaud, Switzerland, 344, 349, 352
- Victoria, Australia, 125–26, 132–36, 150
- Waiting lists, 268, 308, 336 (*see also* Queues); in Canada, 94, 97, 106, 111; in Denmark, 252, 256, 257, 259
- Western Australia, 133, 136, 150
- Western Australia Minimum Data Set, 132
- Western Australian Centre of Health Services Research database, 126
- Winnipeg, Manitoba, 107–8, 111
- World Health Organization (WHO), 6, 264, 363. *See also* MONICA Project